FARCO-PHARMA acquires MedTech Startup Purenum GmbH
Successful Exit for HTGF
FARCO-PHARMA, a company of the Klosterfrau Healthcare Group, is acquiring Purenum GmbH, which was founded in 2017. The MedTech start-up will operate as a wholly owned subsidiary of FARCO-PHARMA and will continue to drive forward its work in the area of research & development. The seed investor High-Tech Gründerfonds (HTGF), the investment company of BAB – Die Förderbank and FRIBA Investment have closely supported Purenum GmbH since 2018 and are selling their shares as part of the acquisition.
Purenum develops and researches new adhesives and hydrogel systems for applications in the medical environment. Purenum GmbH is a spin-off of the Bremen Fraunhofer Institute for Manufacturing Technology and Applied Materials Research (IFAM), where the two founders Dipl.-Ing. (MBA) Manfred Peschka and Prof. Dr. Ingo Grunwald had previously worked and researched in the field of bioadhesives for many years.
mediNiK®, the first certified medical product from Purenum GmbH, represents a significant advance in the endoscopic removal of kidney stones. The medical hydrogel does not adhere to surgical instruments or the sensitive renal mucosa, is biocompatible and makes it possible to remove even the smallest remnants of kidney stones endoscopically.
Thus mediNiK® fulfils a long overdue medical need. Because often smaller kidney stone fragments remain in the kidney after an operation because they are too small for the gripping instruments (< 1 millimetre). For the body, however, these can continue to be a burden, as larger stones can form again, which can lead to renewed complaints. In Germany, three to five percent of the population suffer from kidney stones.1
HTGF has closely supported Purenum GmbH over the past five years. In addition to HTGF, BAB – Förderbank für Bremen und Bremerhaven and FRIBA Investment have invested in the start-up. The project was funded by the Federal Ministry of Education and Research (BMBF) as part of the GO-Bio initiative.
"mediNiK® as a product and thus also the development performance of the Purenum team have impressed and convinced us so much that we are very pleased to be able to develop and offer the helpful product mediNiK® worldwide as FARCO-PHARMA together with Purenum. We look forward to investing further in research together with the Purenum team and thus working consistently on optimising patient care", Dr Marc Vollenbröker, Managing Director of FARCO-PHARMA GmbH.
"Thanks to many years of experience in the field of urological gels and the resulting trust of specialists, FARCO-PHARMA is the ideal partner for Purenum", Manfred Peschka, Managing Director of Purenum GmbH.
"FARCO-PHARMA is an excellent fit as a strategic partner due to their market-leading position and special expertise in urology. Purenum founders Manfred Peschka and Ingo Grunwald deserve great recognition for driving the development forward with tireless commitment. We wish them much success on their common path!" Dr. Anke Caßing, Principal at HTGF.
"We are pleased that the founders Manfred Peschka and Ingo Grunwald have succeeded in developing their product and building up their company in such a positive. We wish them every success for their further development and their new path together. We are excited to see how the success story will continue", Managing Director of BAB’s investment company.
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
Most read news
More news from our other portals
Something is happening in the life science industry ...
This is what true pioneering spirit looks like: Plenty of innovative start-ups are bringing fresh ideas, lifeblood and entrepreneurial spirit to change tomorrow's world for the better. Immerse yourself in the world of these young companies and take the opportunity to get in touch with the founders.
